SCHEMBL3941980

SCHEMBL3941980

CNC(=O)c1ccc(C#C[Si](C)(C)C)cc1

nearest known ligand 0.50

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HDAC6 Q9UBN7 2/20 0.50
HDAC2 Q92769 1/20 0.50
HDAC8 Q9BY41 1/20 0.50
ACACB O00763 1/20 0.48
GRM5 P41594 1/20 0.48
HPGD P15428 1/20 0.47
TSHR P16473 1/20 0.47
HTT P42858 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
PLK1 P53350 8/20 0.46
CA2 P00918 1/20 0.43
MMP13 P45452 2/20 0.42
MKNK1 Q9BUB5 1/20 0.41
MKNK2 Q9HBH9 1/20 0.41
HDAC4 P56524 1/20 0.40
MMP2 P08253 1/20 0.39
RARB P10826 1/20 0.39
RARG P13631 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16198925 0.85 HDAC2 (0.61) HDAC6HDAC2HDAC8ACACBGRM5
SCHEMBL15284661 0.82 HDAC8 (0.41) HDAC6HDAC2HDAC8GRM5HPGD
SCHEMBL8049735 0.81 ALDH1A1 (0.43) HPGDHTTSMN1; SMN2RARBRARG
SCHEMBL4161682 0.80 HDAC8 (0.51) HDAC6HDAC8GRM5PLK1MKNK2
SCHEMBL18472972 0.79 HDAC2 (0.55) HDAC6HDAC2HDAC8ACACBGRM5
SCHEMBL6036758 0.79 RARB (0.55) ACACBHPGDTSHRSMN1; SMN2CA2
SCHEMBL9636621 0.79 HPGD (0.47) ACACBHPGDSMN1; SMN2RARBRARG
SCHEMBL168698 0.79 PTPN11 (0.54) HPGDTSHRCA2
SCHEMBL20040174 0.79 GRM5 (0.32) ACACBGRM5
SCHEMBL25093690 0.78 NOS1 (0.44) GRM5TSHRSMN1; SMN2CA2MKNK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090069321-A1 CYANOMETHYL SUBSTITUTED N-ACYL TRYPTAMINES BAYER SCHERING PHARMA AG (DE) 2009-03-12 US disclosed
WO-2009016253-A2 CYANOMETHYL SUBSTITUTED N-ACYL TRYPTAMINES BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2009-02-05 WO disclosed
EP-2020404-A1 Cyanomethyl substituted N-Acyl Tryptamines Bayer Schering Pharma Aktiengesellschaft (DE) 2009-02-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090069321-A1 CYANOMETHYL SUBSTITUTED N-ACYL TRYPTAMINES FSHR, GNRHR, HNMT HDAC6 1283/4885HDAC2 1069/4885HDAC8 2309/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.